Market Overview:
The global antivenin market is expected to grow at a CAGR of 6.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of snakebites, rising demand for polyvalent antivenins, and technological advancements in the field of venom detection and treatment. However, factors such as high cost of antivenins and lack of awareness about snakebite prevention may restrain the growth of this market during the forecast period. Based on type, the global antivenin market is segmented into polyvalent and monovalent segments. The polyvalent segment is expected to account for a larger share than the monovalent segment during the forecast period owing to its ability to neutralize multiple types of venomous snakes’ bites. Based on application, hospitals and clinics are expected to account for a larger share than non-profit institutions duringthe forecast period owingto their greater need for these products due topoisoning cases caused by snakebites annually .
Product Definition:
A serum or other preparation that counteracts the effects of venom, especially one used to treat snakebites.
Polyvalent:
Polyvalent refers to an antibody that is capable of binding more than one antigen. The most common example of this is the antibody that occurs in the form of a dimer, which binds two antigens on an epitope and is therefore called a bispecific or bifunctional antibody.
Monovalent:
Monovalent antivenin is a specific antibody that works only against one type of venom. It has higher efficacy than bivalent or multipurpose antivenin and hence is used in the treatment of severe allergic reactions caused by bites from highly potent venoms such as Crotaline, Bitembo, and Napecolac.
Application Insights:
On the basis of application, the global antivenin market has been segmented into hospitals and clinics and non-profit institutions. Hospitals and clinics held the largest share in 2017 due to availability of advanced healthcare facilities along with highly skilled personnel. This is also supported by a high incidence rate of animal bites across the globe which results in requirement for large quantities of antivenin.
Non-profit institutions are expected to witness fastest growth over forecast period owing to growing awareness about availability of low cost treatment options especially for rare diseases which have not been covered under insurance schemes or government subsidies. Rising incidences of snakebite cases coupled with increasing number health consciousness among population particularly in emerging markets such as China, India & Brazil will boost product demand over next few years.
Regional Analysis:
Asia Pacific dominated the global market in 2017, accounting for a share of over 45%. The presence of emerging economies such as China and India has led to an increase in the number of snakebite cases. Moreover, increasing incidence of envenoming attacks by snakes is another factor contributing to regional growth.
The majority share can also be attributed to high demand for antivenins globally. North America is expected to grow at a significant rate over the forecast period owing to rising incidence rates and improved treatment options through new drug development programs. Furthermore, growing awareness about venomous animal bites and availability of effective treatment will drive this regional market further. Europe accounted for more than 20% share in 2017 due its large production facilities along with high healthcare expenditure per capita compared with other regions (USD X). However, low adoption rate coupled with lacklustre product quality may hinder future growth prospects within this region.
Growth Factors:
- Increasing incidence of snakebites: The increasing incidence of snakebites is one of the key growth drivers for the antivenin market. According to a study by the World Health Organization (WHO), an estimated 5 million people are bitten by snakes every year, out of which 100,000 die. This number is expected to rise in future due to the increasing population and expanding geographical areas where venomous snakes are found.
- Growing demand for effective and safe antivenins: The growing demand for effective and safe antivenins is another major growth driver for this market. With an increase in awareness about snakebite treatment options, patients are increasingly demanding better-quality products that can provide them with relief from symptoms quickly. This has led to a surge in demand for high-quality antivenins such as Anavip, Antivipmyn, etc., which offer faster relief from symptoms than traditional therapies like antibiotics or corticosteroids.
- Technological advancements: The advent of new technologies has led to significant advancements in the field of venom research and development (R&D). This has resulted in the emergence of novel therapeutics such as monoclonal antibodies (mAbs) that show promise against various types of venoms including those from snakes, spiders, scorpions, etc., thereby boosting growth prospects for this market over the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Antivenin Market Research Report
By Type
Polyvalent, Monovalent
By Application
Hospitals and Clinics, Non-profit Institutions
By Companies
CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech, CSL, CSL
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
124
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Antivenin Market Report Segments:
The global Antivenin market is segmented on the basis of:
Types
Polyvalent, Monovalent
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Non-profit Institutions
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL
- Merck
- BTG
- Pfizer
- Haffkine Bio-Pharmaceutical
- Rare Disease Therapeutics
- Flynn Pharma
- Vins Bioproducts
- Bharat Serums and Vaccines
- Serum Biotech
- CSL
- CSL
Highlights of The Antivenin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Polyvalent
- Monovalent
- By Application:
- Hospitals and Clinics
- Non-profit Institutions
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antivenin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Antivenin is a serum that neutralizes the venom of snakes.
Some of the key players operating in the antivenin market are CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech, CSL, CSL.
The antivenin market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antivenin Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Antivenin Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Antivenin Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Antivenin Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Antivenin Market Size & Forecast, 2018-2028 4.5.1 Antivenin Market Size and Y-o-Y Growth 4.5.2 Antivenin Market Absolute $ Opportunity
Chapter 5 Global Antivenin Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Antivenin Market Size Forecast by Type
5.2.1 Polyvalent
5.2.2 Monovalent
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Antivenin Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Antivenin Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Non-profit Institutions
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Antivenin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antivenin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antivenin Analysis and Forecast
9.1 Introduction
9.2 North America Antivenin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antivenin Market Size Forecast by Type
9.6.1 Polyvalent
9.6.2 Monovalent
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Antivenin Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Non-profit Institutions
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Antivenin Analysis and Forecast
10.1 Introduction
10.2 Europe Antivenin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antivenin Market Size Forecast by Type
10.6.1 Polyvalent
10.6.2 Monovalent
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Antivenin Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Non-profit Institutions
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Antivenin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antivenin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antivenin Market Size Forecast by Type
11.6.1 Polyvalent
11.6.2 Monovalent
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Antivenin Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Non-profit Institutions
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Antivenin Analysis and Forecast
12.1 Introduction
12.2 Latin America Antivenin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antivenin Market Size Forecast by Type
12.6.1 Polyvalent
12.6.2 Monovalent
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Antivenin Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Non-profit Institutions
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Antivenin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antivenin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antivenin Market Size Forecast by Type
13.6.1 Polyvalent
13.6.2 Monovalent
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Antivenin Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Non-profit Institutions
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Antivenin Market: Competitive Dashboard
14.2 Global Antivenin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CSL
14.3.2 Merck
14.3.3 BTG
14.3.4 Pfizer
14.3.5 Haffkine Bio-Pharmaceutical
14.3.6 Rare Disease Therapeutics
14.3.7 Flynn Pharma
14.3.8 Vins Bioproducts
14.3.9 Bharat Serums and Vaccines
14.3.10 Serum Biotech
14.3.11 CSL
14.3.12 CSL